Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02910414 · ClinicalTrials.gov registry record · Phase 3
TARGET BP I Clinical Trial
A Phase 3 study of Hypertension, sponsored by Ablative Solutions.
- Active
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 5
- Study locations
NCT02910414 is a Phase 3 study of Hypertension that is active but no longer recruiting, run by Ablative Solutions. The registered enrollment target is 300 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (91% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT02910414, a Phase 3 study of Hypertension, is active but no longer recruiting, sponsored by Ablative Solutions.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 5
- Study locations
Study Summary
The TARGET BP I Trial is a randomized, blinded, multi-center, international, sham-procedure controlled trial, comparing renal denervation performed with the Peregrine System Kit in the treatment group to the sham control group (without renal denervation - no alcohol infusion). Subjects will be randomized in a 1:1 fashion to treatment versus sham control via central randomization.
Conditions Studied
Interventions
- DRUG Dehydrated alcohol
- DEVICE Peregrine System Kit (Sham Procedure)
Study Locations (5)
North Carolina
- NC Heart and Vascular Research - Raleigh
- Wake Forest University Baptist Medical Center - Winston-Salem
Alabama
- Cardiology PC - Birmingham
Georgia
- Piedmont Heart Institute - Atlanta
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2019-07-22 |
| Est. Completion | 2026-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02910414
The ClinicalTrials.gov registry entry for NCT02910414 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (91% lower). The listed sponsor is Ablative Solutions, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Dehydrated alcohol is the first listed.
NCT02910414 reports 5 study locations spanning 4 distinct geographic areas - top geographies include North Carolina, Alabama, Georgia.
Frequently Asked Questions
What is clinical trial NCT02910414 about?
NCT02910414 is a clinical study titled "TARGET BP I Clinical Trial". The TARGET BP I Trial is a randomized, blinded, multi-center, international, sham-procedure controlled trial, comparing renal denervation performed with the Peregrine System Kit in the treatment group to the sham control group (without renal denervation - no alcohol infusion). Subjects will be rando...
What is the current status of trial NCT02910414?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2019-07-22. Estimated completion is 2026-05.
What conditions does trial NCT02910414 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT02910414?
The interventions under investigation include: Dehydrated alcohol (DRUG), Peregrine System Kit (Sham Procedure) (DEVICE).
Who is sponsoring clinical trial NCT02910414?
This trial is sponsored by Ablative Solutions, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02910414 being conducted?
This trial has 5 study locations across Alabama, Georgia, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.